Talkspace vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Talkspace is an online therapy platform connecting users with licensed therapists via text, audio, and video, with coverage through major health plans and employers.
About
Talkspace is an online mental health company founded in 2012 that has become one of the most widely known telehealth therapy platforms, serving millions of users through its network of licensed therapists. The platform allows users to connect with therapists via asynchronous text messaging, live video sessions, and audio calls, offering flexibility that traditional in-person therapy cannot match. Talkspace is publicly traded on Nasdaq and generates a significant portion of revenue through health insurance coverage, with contracts including UnitedHealthcare, Cigna, and Aetna making therapy accessible to insured members. The company also offers a Talkspace for Business product serving employers as a mental health employee benefit. Talkspace has faced the challenge of demonstrating clinical outcomes comparable to in-person therapy while operating at a lower cost per session, and has invested in outcomes research to build evidence for its asynchronous text therapy modality. The company serves a broad range of mental health needs including anxiety, depression, relationship issues, and trauma, and has expanded into psychiatry for medication management. Talkspace operates in a competitive market alongside BetterHelp and other teletherapy platforms.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.